世界のコンパニオン診断市場(~2026年):製品別(アッセイ、キット、ソフトウェア&サービス)、技術別(PCR、NGS、ISH、IHC)、疾患別(乳房、血液、肺、結腸直腸癌、神経疾患)、エンドユーザー別(製薬会社、CRO)、地域別

◆英語タイトル:Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026

MarketsandMarketsが発行した調査報告書(MD5463)◆商品コード:MD5463
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2022年2月8日
◆ページ数:332
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User(5名様閲覧)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License(法人閲覧)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

マーケッツアンドマーケッツ社は、世界のコンパニオン診断市場規模が、2021年55億ドルから2026年99億ドルまで年平均12.6%成長すると予測しています。本調査レポートは、コンパニオン診断の世界市場について広く調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(アッセイ・キット・試薬、ソフトウェア・サービス)分析、技術別(PCR、NGS、ISH、IHC、その他)分析、疾患別(癌、感染症、心血管疾患、神経疾患、その他)分析、エンドユーザー別(製薬・バイオテクノロジー企業、リファレンスラボ、CRO、その他)分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のコンパニオン診断市場規模:製品別(アッセイ・キット・試薬、ソフトウェア・サービス)
・世界のコンパニオン診断市場規模:技術別(PCR、NGS、ISH、IHC、その他)
・世界のコンパニオン診断市場規模:疾患別(癌、感染症、心血管疾患、神経疾患、その他)
・世界のコンパニオン診断市場規模:エンドユーザー別(製薬・バイオテクノロジー企業、リファレンスラボ、CRO、その他)
・世界のコンパニオン診断市場規模:地域別
・競争状況
・企業情報

“The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period.”
Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

“The assays, kits & reagents segment accounted for the highest growth rate in the companion diagnostics market, by product & service, during the forecast period.”
Based on product & service, the companion diagnostics market is segmented into assays, kits & reagents, and software & services. In 2020, assays, kits & reagents accounted for the largest share of the companion diagnostics market due to the availability of a wide range of products, increasing use of assays and kits in different therapeutic areas, and the growing demand for assays and kits in basic research and commercial applications.

“Pharmaceutical & biotechnology companies segment accounted for the highest CAGR.”
Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users. In 2020, pharmaceutical & biotechnology companies were the largest end users of companion diagnostics. This can primarily be attributed to the growing use of companion diagnostics owing to their increasing prominence in drug development and the increasing importance of companion diagnostic biomarkers. The rising demand for personalized medicine, as well as the high need for targeted therapies for various diseases and disorders, are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biotechnology companies.

“North America is the largest regional market for companion diagnostics market.”
The global companion diagnostics market has been segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest regional market for companion diagnostics. The large share of North America in this market can be attributed to the presence of many leading companion diagnostics vendors & national clinical laboratories, the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6% , and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

Research Coverage:
This report provides a detailed picture of the companion diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, indication, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

❖ レポートの目次 ❖

1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 29
1.3 MARKETS COVERED 29
FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION 29
1.3.1 YEARS CONSIDERED FOR THE STUDY 30
1.4 CURRENCY 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 2 COMPANION DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 32
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 33
2.1.2 PRIMARY DATA 34
2.1.2.1 Primary sources 35
2.1.2.2 Key data from primary sources 36
2.1.2.3 Key industry insights 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 37
2.2 MARKET SIZE ESTIMATION 38
2.2.1 BOTTOM-UP APPROACH 38
2.2.1.1 Approach 1: Company revenue estimation approach 38
FIGURE 4 COMPANION DIAGNOSTICS MARKET: BOTTOM-UP APPROACH 38
2.2.1.2 Approach 2: Presentations of companies and primary interviews 39
2.2.1.3 Growth forecast (2021–2026) 39
2.2.1.4 CAGR projections 39
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 39
2.2.2 TOP-DOWN APPROACH 40
FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH 40
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 41
FIGURE 7 DATA TRIANGULATION METHODOLOGY 41
2.4 MARKET SHARE ANALYSIS 42
2.5 ASSUMPTIONS FOR THE STUDY 42
2.6 LIMITATIONS 43
2.7 RISK ASSESSMENT 43
2.7.1 RISK ASSESSMENT: COMPANION DIAGNOSTICS MARKET 43
2.8 GROWTH RATE ASSUMPTIONS 44
2.9 COVID-19 HEALTH ASSESSMENT 44
2.10 COVID-19 ECONOMIC ASSESSMENT 44
2.11 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO 45
FIGURE 8 CRITERIA IMPACTING GLOBAL ECONOMY 45
FIGURE 9 RECOVERY SCENARIO OF GLOBAL ECONOMY 46
2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN COMPANION DIAGNOSTICS MARKET 47
3 EXECUTIVE SUMMARY 48
FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 48
FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 49
FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021 VS. 2026 (USD MILLION) 50
FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 50
FIGURE 14 COMPANION DIAGNOSTICS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 51
4 PREMIUM INSIGHTS 52
4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 52
FIGURE 15 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 52
4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 53
FIGURE 16 ASSAYS, KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2026 53
4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026 53
FIGURE 17 POLYMERASE CHAN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 53
4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2021 VS. 2026 54
FIGURE 18 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 54
4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026 54
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2026 54
4.6 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Advantages of companion diagnostics 57
5.2.1.1.1 Growing need for targeted therapy 57
5.2.1.1.2 Rising importance of personalized medicine 58
FIGURE 22 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2020 58
FIGURE 23 GROWTH IN US FDA PERSONALIZED MEDICINE APPROVAL RATE, 2015–2020 58
5.2.1.1.3 Increasing global incidence of cancer 59
FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030 59
5.2.1.1.4 Growing application areas of companion diagnostics 59
5.2.2 RESTRAINTS 60
5.2.2.1 High capital investment and low cost-benefit ratio 60
5.2.2.2 Expensive companion diagnostic tests 60
5.2.2.3 Uncertain reimbursement scenario in different regions 60
TABLE 1 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE 61
5.2.2.4 High cost of immunotherapy treatment 62
TABLE 2 COST OF KEYTRUDA, BY REGION (2018) 62
5.2.3 OPPORTUNITIES 62
5.2.3.1 Increasing demand for next-generation sequencing 62
TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS 63
5.2.3.2 Growing significance of companion diagnostics in drug development 63
5.2.3.3 Higher number of clinical trials 64
TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS 64
5.2.4 CHALLENGES 65
5.2.4.1 Shortage of trained professionals 65
5.2.4.2 Lack of awareness of companion diagnostics testing 66
5.3 IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET 66
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS 67
5.4.1 COMPANION DIAGNOSTICS MARKET 67
FIGURE 25 PESSIMISTIC SCENARIO 67
FIGURE 26 OPTIMISTIC SCENARIO 68
FIGURE 27 REALISTIC SCENARIO 68
5.5 PRICING ANALYSIS 69
TABLE 5 PRICE OF COMPANION DIAGNOSTICS PRODUCT & SERVICE (2021) 69
5.6 PATENT ANALYSIS 70
FIGURE 28 PATENT ANALYSIS OF COMPANION DIAGNOSTICS MARKET 70
5.7 TRADE ANALYSIS 71
5.7.1 TRADE ANALYSIS FOR COMPANION DIAGNOSTICS 71
TABLE 6 IMPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY,
2016–2020 (USD MILLION) 71
TABLE 7 EXPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY,
2016–2020 (USD MILLION) 72
5.8 VALUE CHAIN ANALYSIS 72
FIGURE 29 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE 73
5.9 SUPPLY CHAIN ANALYSIS 73
FIGURE 30 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 74
5.10 ECOSYSTEM ANALYSIS OF COMPANION DIAGNOSTICS MARKET 75
FIGURE 31 COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 75
5.10.1 ROLE IN ECOSYSTEM 75
5.11 PORTER’S FIVE FORCES ANALYSIS 76
TABLE 8 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 76
5.11.1 THREAT OF NEW ENTRANTS 76
5.11.2 THREAT OF SUBSTITUTES 76
5.11.3 BARGAINING POWER OF BUYERS 76
5.11.4 BARGAINING POWER OF SUPPLIERS 76
5.11.5 DEGREE OF COMPETITION 77
5.12 REGULATORY LANDSCAPE 77
5.12.1 NORTH AMERICA 77
5.12.1.1 US 77
5.12.1.2 Canada 77
5.12.2 EUROPE 77
5.12.3 ASIA PACIFIC 77
5.12.3.1 China 77
5.12.3.2 Japan 78
5.12.3.3 India 78
5.12.4 LATIN AMERICA 78
5.12.4.1 Brazil 78
5.12.4.2 Mexico 78
5.12.5 MIDDLE EAST 79
5.13 TECHNOLOGY ANALYSIS 79
5.14 PESTLE ANALYSIS 80
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS 81
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 PANDEMIC 81
5.15.2 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET 81
6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 82
6.1 INTRODUCTION 83
TABLE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2020 (USD MILLION) 83
TABLE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 83
6.2 ASSAYS, KITS & REAGENTS 83
6.2.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS 83
TABLE 11 KEY PRODUCTS IN ASSAYS AND KITS, BY COMPANY 84
TABLE 12 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 85
TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 86
6.3 SOFTWARE & SERVICES 87
6.3.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH 87
TABLE 14 KEY PRODUCTS IN SOFTWARE & SERVICES, BY COMPANY 87
TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION) 88
TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 89
7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 90
7.1 INTRODUCTION 91
TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 91
TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 91
7.2 POLYMERASE CHAIN REACTION (PCR) 92
7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH 92
TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION 92
TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE 92
TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2017–2020 (USD MILLION) 93
TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2021–2026 (USD MILLION) 94
7.3 NEXT-GENERATION SEQUENCING 95
7.3.1 EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD 95
TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE 95
TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017–2020 (USD MILLION) 96
TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2021–2026 (USD MILLION) 97
7.4 IN SITU HYBRIDIZATION 98
7.4.1 INCREASING DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH 98
TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE 98
TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2017–2020 (USD MILLION) 99
TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2021–2026 (USD MILLION) 100
7.5 IMMUNOHISTOCHEMISTRY (IHC) 101
7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH 101
TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE 101
TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2017–2020 (USD MILLION) 102
TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2021–2026 (USD MILLION) 103
7.6 OTHER TECHNOLOGIES 103
TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2017–2020 (USD MILLION) 104
TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2021–2026 (USD MILLION) 105
8 COMPANION DIAGNOSTICS MARKET, BY INDICATION 106
8.1 INTRODUCTION 107
TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 107
TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 107
8.2 CANCER 108
TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2017–2020 (USD MILLION) 108
TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE,
2021–2026 (USD MILLION) 109
TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,
2017–2020 (USD MILLION) 109
TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,
2021–2026 (USD MILLION) 110
8.2.1 LUNG CANCER 111
8.2.1.1 Growing demand for effective therapeutic drugs to increase CDX adoption 111
FIGURE 32 GLOBAL LUNG CANCER INCIDENCE, 2012–2030 111
TABLE 40 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017–2020 (USD MILLION) 112
TABLE 41 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2026 (USD MILLION) 113
8.2.2 BREAST CANCER 114
8.2.2.1 Wide prevalence of breast cancer among women contributes to large size of segment 114
TABLE 42 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2030 114
TABLE 43 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017–2020 (USD MILLION) 115
TABLE 44 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2026 (USD MILLION) 116
8.2.3 BLOOD CANCER 117
8.2.3.1 Increasing incidence of disease to boost market 117
TABLE 45 BLOOD CANCER INCIDENCE, BY REGION, 2020 VS. 2030 117
TABLE 46 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2017–2020 (USD MILLION) 118
TABLE 47 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2026 (USD MILLION) 119
8.2.4 COLORECTAL CANCER 119
8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth 119
TABLE 48 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2017–2020 (USD MILLION) 120
TABLE 49 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2021–2026 (USD MILLION) 121
8.2.5 OTHER CANCERS 122
TABLE 50 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017–2020 (USD MILLION) 122
TABLE 51 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2026 (USD MILLION) 123
8.3 INFECTIOUS DISEASES 123
8.3.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH 123
TABLE 52 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2017–2020 (USD MILLION) 124
TABLE 53 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DIESEASES,
BY COUNTRY, 2021–2026 (USD MILLION) 125
8.4 CARDIOVASCULAR DISEASES 125
8.4.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH 125
TABLE 54 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2017–2020 (USD MILLION) 126
TABLE 55 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2021–2026 (USD MILLION) 127
8.5 NEUROLOGICAL DISEASES 127
8.5.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS 127
TABLE 56 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES,
BY COUNTRY, 2017–2020 (USD MILLION) 128
TABLE 57 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES,
BY COUNTRY, 2021–2026 (USD MILLION) 129
8.6 OTHER INDICATIONS 129
TABLE 58 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2020 (USD MILLION) 130
TABLE 59 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2026 (USD MILLION) 131
9 COMPANION DIAGNOSTICS MARKET, BY END USER 132
9.1 INTRODUCTION 133
TABLE 60 COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 133
TABLE 61 COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 133
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 134
9.2.1 INCREASING USE OF CDX IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH 134
TABLE 62 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017–2020 (USD MILLION) 134
TABLE 63 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION) 135
9.3 REFERENCE LABORATORIES 135
9.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH 135
TABLE 64 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2017–2020 (USD MILLION) 136
TABLE 65 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2021–2026 (USD MILLION) 137
9.4 CONTRACT RESEARCH ORGANIZATIONS 137
9.4.1 SIGNIFICANT DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS 137
TABLE 66 COMPANION DIAGNOSTICS MARKET FOR CRO, BY COUNTRY,
2017–2020 (USD MILLION) 138
TABLE 67 COMPANION DIAGNOSTICS MARKET FOR CRO BY COUNTRY,
2021–2026 (USD MILLION) 139
9.5 OTHER END USERS 139
TABLE 68 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2020 (USD MILLION) 140
TABLE 69 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION) 141
10 COMPANION DIAGNOSTICS MARKET, BY REGION 142
10.1 INTRODUCTION 143
TABLE 70 COMPANION DIAGNOSTICS MARKET, BY REGION,
2017–2020 (USD MILLION) 143
TABLE 71 COMPANION DIAGNOSTICS MARKET, BY REGION,
2021–2026 (USD MILLION) 143
10.2 NORTH AMERICA 144
TABLE 72 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER 145
FIGURE 33 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 145
FIGURE 34 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT 146
TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 147
TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 147
TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 147
TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 148
TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 148
TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 149
TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION) 149
TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION) 150
TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 150
TABLE 82 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 151
TABLE 83 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION) 151
TABLE 84 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 152
10.2.1 US 152
10.2.1.1 Increasing use of companion diagnostics for cancer treatment boosts market 152
TABLE 85 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 153
TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2020 (USD MILLION) 153
TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 154
TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 154
TABLE 89 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 154
TABLE 90 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 155
TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 155
TABLE 92 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 156
TABLE 93 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 156
TABLE 94 US: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 157
TABLE 95 US: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 157
10.2.2 CANADA 157
10.2.2.1 Increasing government initiatives expected to drive market 157
TABLE 96 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 159
TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 159
TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 159
TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 160
TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 160
TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 161
TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 161
TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 162
TABLE 104 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 162
TABLE 105 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 163
TABLE 106 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 163
10.3 EUROPE 164
FIGURE 35 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 165
TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 165
TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 166
TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 166
TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 166
TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 167
TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 167
TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 168
TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 168
TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 169
TABLE 116 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 169
TABLE 117 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 170
TABLE 118 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 170
10.3.1 GERMANY 170
10.3.1.1 Favorable government policies to drive market 170
TABLE 119 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 171
TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 172
TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 172
TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 172
TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 173
TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 173
TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 174
TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 174
TABLE 127 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 175
TABLE 128 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 175
TABLE 129 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 176
10.3.2 UK 176
10.3.2.1 Growing life science industry and increasing focus on research to propel market 176
TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2020 (USD MILLION) 177
TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 177
TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 178
TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 178
TABLE 134 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 179
TABLE 135 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 179
TABLE 136 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 180
TABLE 137 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 180
TABLE 138 UK: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 181
TABLE 139 UK: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 181
10.3.3 SWITZERLAND 181
10.3.3.1 Strong research-oriented pharma industry supports market growth 181
TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 182
TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 182
TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 183
TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 183
TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 184
TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 184
TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 185
TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 185
TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 186
TABLE 149 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 186
10.3.4 FRANCE 186
10.3.4.1 Increasing government funding for research to support market growth 186
TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 187
TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 188
TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 188
TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 189
TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 189
TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 190
TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 190
TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 191
TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 191
TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 192
10.3.5 ITALY 192
10.3.5.1 Growing demand for better and more powerful therapeutics 192
TABLE 160 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2020 (USD MILLION) 193
TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 193
TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 194
TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 194
TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 195
TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 195
TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 196
TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 196
TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 197
TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 197
10.3.6 SPAIN 197
10.3.6.1 Increasing focus on advancement of personalized medicine to drive market growth 197
TABLE 170 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 198
TABLE 171 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 199
TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 199
TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 200
TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 200
TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 201
TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 201
TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 202
TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 202
TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 202
10.3.7 REST OF EUROPE 203
TABLE 180 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2020 (USD MILLION) 203
TABLE 181 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 203
TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 204
TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 204
TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 205
TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 205
TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 206
TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 206
TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 207
TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 207

10.4 ASIA PACIFIC 207
FIGURE 36 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 208
FIGURE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT 209
TABLE 190 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 210
TABLE 191 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 210
TABLE 192 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 211
TABLE 193 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 211
TABLE 194 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 211
TABLE 195 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 212
TABLE 196 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 212
TABLE 197 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 213
TABLE 198 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 213
TABLE 199 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 214
TABLE 200 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 214
TABLE 201 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 215
10.4.1 CHINA 215
10.4.1.1 Growing public access to advanced healthcare facilities to drive market 215
TABLE 202 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 216
TABLE 203 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 216
TABLE 204 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 217
TABLE 205 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 217
TABLE 206 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 218
TABLE 207 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 218
TABLE 208 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 219
TABLE 209 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 219
TABLE 210 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 220
TABLE 211 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 220
10.4.2 JAPAN 220
10.4.2.1 Research initiatives supporting market growth 220
TABLE 212 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 221
TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 221
TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 222
TABLE 215 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 222
TABLE 216 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 223
TABLE 217 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 223
TABLE 218 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 224
TABLE 219 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 224
TABLE 220 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 225
TABLE 221 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 225
TABLE 222 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 226
10.4.3 INDIA 226
10.4.3.1 Increased demand for early cancer diagnosis to support market growth 226
TABLE 223 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 227
TABLE 224 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2017–2020 (USD MILLION) 227
TABLE 225 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2021–2026 (USD MILLION) 228
TABLE 226 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 228
TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 229
TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 229
TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 230
TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 230
TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 231
TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 231
TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 232
10.4.4 AUSTRALIA 232
10.4.4.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market 232
TABLE 234 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 233
TABLE 235 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 233
TABLE 236 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 234
TABLE 237 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 234
TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 235
TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 235
TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 236
TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 236
TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 237
TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 237
10.4.5 REST OF ASIA PACIFIC 237
TABLE 244 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 238
TABLE 245 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 239
TABLE 246 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 239
TABLE 247 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 240
TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 240
TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 241
TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 241
TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 242
TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 242
TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 243
10.5 LATIN AMERICA 243
TABLE 254 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 244
TABLE 255 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 244
TABLE 256 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 245
TABLE 257 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 245
TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION) 245
TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 246
TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION) 246
TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION) 247
TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 247
TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 248
TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 248
TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 249
10.5.1 BRAZIL 249
10.5.1.1 Increasing incidence of lifestyle diseases drives market 249
TABLE 266 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 250
TABLE 267 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 250
TABLE 268 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 250
TABLE 269 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 251
TABLE 270 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 251
TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 252
TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 252
TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 253
TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 253
TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 254
10.5.2 MEXICO 254
10.5.2.1 Growing medical tourism to fuel demand for companion diagnostics 254
TABLE 276 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 255
TABLE 277 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 255
TABLE 278 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 255
TABLE 279 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 256
TABLE 280 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 256
TABLE 281 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 257
TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2017–2020 (USD MILLION) 257
TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE,
2021–2026 (USD MILLION) 258
TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 258
TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 258
10.5.3 REST OF LATIN AMERICA 259
TABLE 286 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 259
TABLE 287 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 259
TABLE 288 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2017–2020 (USD MILLION) 260
TABLE 289 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 260
TABLE 290 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2017–2020 (USD MILLION) 261
TABLE 291 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2021–2026 (USD MILLION) 261
TABLE 292 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 262
TABLE 293 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 262
TABLE 294 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER,
2017–2020 (USD MILLION) 263
TABLE 295 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER,
2021–2026 (USD MILLION) 263
10.6 MIDDLE EAST & AFRICA 263
10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH 263
TABLE 296 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2017–2020 (USD MILLION) 264
TABLE 297 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2021–2026 (USD MILLION) 265
TABLE 298 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2017–2020 (USD MILLION) 265
TABLE 299 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2021–2026 (USD MILLION) 266
TABLE 300 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET,
BY INDICATION, 2017–2020 (USD MILLION) 266
TABLE 301 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET,
BY INDICATION, 2021–2026 (USD MILLION) 267
TABLE 302 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION) 267
TABLE 303 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION) 268
TABLE 304 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION) 268
TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION) 269
11 COMPETITIVE LANDSCAPE 270
11.1 OVERVIEW 270
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 270
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET 271
TABLE 306 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANION DIAGNOSTICS MANUFACTURING COMPANIES 271
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 272
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICS MARKET (2015-2020) 272
11.4 MARKET SHARE ANALYSIS 273
FIGURE 39 COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020) 273
TABLE 307 COMPANION DIAGNOSTICSMARKET: DEGREE OF COMPETITION 273
11.5 COMPANY EVALUATION QUADRANT 274
11.5.1 LIST OF EVALUATED VENDORS 274
11.5.2 STARS 274
11.5.3 EMERGING LEADERS 275
11.5.4 PERVASIVE PLAYERS 275
11.5.5 PARTICIPANTS 275
FIGURE 40 COMPANION DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP
MAPPING, 2020 275
11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020) 276
11.6.1 PROGRESSIVE COMPANIES 276
11.6.2 STARTING BLOCKS 276
11.6.3 RESPONSIVE COMPANIES 276
11.6.4 DYNAMIC COMPANIES 276
FIGURE 41 COMPANION DIAGNOSTICSMARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020 277
11.7 COMPETITIVE BENCHMARKING 278
11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 278
FIGURE 42 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICSMARKET 278
TABLE 308 PRODUCT FOOTPRINT OF COMPANIES 278
TABLE 309 REGIONAL FOOTPRINT OF COMPANIES 278
11.8 COMPETITIVE SCENARIO 279
11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 279
TABLE 310 KEY PRODUCT LAUNCHES 279

11.8.2 DEALS 280
TABLE 311 KEY DEALS 280
12 COMPANY PROFILES 281
(Business overview, Products offered, Recent developments & MnM View)*
12.1 KEY PLAYERS 281
12.1.1 F. HOFFMANN-LA ROCHE AG 281
TABLE 312 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 281
FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020) 282
12.1.2 AGILENT TECHNOLOGIES, INC. 285
TABLE 313 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 285
FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 286
12.1.3 QIAGEN 289
TABLE 314 QIAGEN: BUSINESS OVERVIEW 289
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2020) 290
12.1.4 THERMO FISHER SCIENTIFIC, INC. 293
TABLE 315 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 293
FIGURE 46 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 294
12.1.5 ABBOTT LABORATORIES, INC. 297
TABLE 316 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW 297
FIGURE 47 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 298
12.1.6 ALMAC GROUP 300
TABLE 317 ALMAC GROUP: BUSINESS OVERVIEW 300
12.1.7 DANAHER CORPORATION 302
TABLE 318 DANAHER CORPORATION: BUSINESS OVERVIEW 302
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 303
12.1.8 ILLUMINA, INC. 305
TABLE 319 ILLUMINA, INC.: BUSINESS OVERVIEW 305
FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 306
12.1.9 BIOMÉRIEUX SA 308
TABLE 320 BIOMÉRIEUX SA: BUSINESS OVERVIEW 308
FIGURE 50 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 309
12.1.10 MYRIAD GENETICS, INC. 310
TABLE 321 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW 310
FIGURE 51 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020) 310
12.1.11 SYSMEX CORPORATION 312
TABLE 322 SYSMEX CORPORATION: BUSINESS OVERVIEW 312
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 313
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

12.2 OTHER PLAYERS 315
12.2.1 ABNOVA CORPORATION 315
12.2.2 GUARDANT HEALTH, INC. 316
12.2.3 ICON PLC 317
12.2.4 BIOGENEX LABORATORIES, INC. 317
12.2.5 INVIVOSCRIBE TECHNOLOGIES 318
12.2.6 ARCHERDX, INC. 318
12.2.7 NG BIOTECH 319
12.2.8 Q² SOLUTIONS 319
12.2.9 AMOY DIAGNOSTICS CO., LTD. 320
12.2.10 ABACUS DIAGNOSTICA OY 320
12.2.11 ASURAGEN INC. 321
12.2.12 SAGA DIAGNOSTICS 321
12.2.13 MESO SCALE DIAGNOSTICS, LLC. 322
12.2.14 CREATIVE BIOLABS 322
13 APPENDIX 323
13.1 DISCUSSION GUIDE 323
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 328
13.3 AVAILABLE CUSTOMIZATIONS 330
13.4 RELATED REPORTS 330
13.5 AUTHOR DETAILS 331

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のコンパニオン診断市場(~2026年):製品別(アッセイ、キット、ソフトウェア&サービス)、技術別(PCR、NGS、ISH、IHC)、疾患別(乳房、血液、肺、結腸直腸癌、神経疾患)、エンドユーザー別(製薬会社、CRO)、地域別(Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆